Jun. 25 at 1:18 PM
$ANVS Seems like radio silence during a time of pivotal trial milestones for the company. February brought the safety board approval. March we heard about the digital biomarkers in the Parkinson's program. We heard about the cash runway to Q3 2026 and then saw
$10M financing occur with the
$1.5M board chair investment to extend runway to 2027. May brought weak results with booking the trial, and larger than expected losses and cash burn rate. -End Transmission. What's up recently? Now we all own a smaller piece of the company, and still just waiting for the next major data release. I GUESS it appears they are executing a Phase 3 program, raising capital to keep it funded, and waiting for the next meaningful clinical catalyst.
